The posted materials are not copyedited. (PE, BD Pharmingen), CD19 (ECD, Beckman-Coulter), CD27 (APC-Cy7, BioLegend), CD38 (Pe-Cy7), and CD138 (APC, BD BioScience). The staining protocol is usually explained elsewhere [13]. Events were collected on a LSRII instrument (BD Biosciences, San Jose, CA), and analysis was performed using FlowJo software (Treestar, version 9.4.11). Nilvadipine (ARC029) Total cell figures were calculated using the routine white blood cell counts collected at each time point. HAI Assay and VNA Serum samples were collected at 2 time points, day 0 and day 30 after vaccination. The HAI assay was performed as previously explained [14]. The hemagglutination inhibition (HI) titer was defined as the reciprocal of the highest dilution of serum that inhibits reddish blood cell hemagglutination. VNA was performed as previously explained [15]. The viral neutralization (VN) titer was defined as the reciprocal of the highest dilution of serum that neutralizes 200 plaque-forming models of influenza computer virus. Seroconversion was based on the following criteria: a 4-fold increase in antibody titers between the prevaccination and the convalescent-phase serum samples or an increase of antibody titers from <10 to 40 for the prevaccination and convalescent-phase serum samples [16C18]. Microarray Data and Statistical Analysis Blood samples were collected in Tempus tubes (Applied Biosystems, CA) and stored at ?20C. RNA was hybridized into Illumina Human WG-6 V4 beadchips (47 323 probes) and scanned around the Illumina Beadstation 500 [19, 20]. Data are deposited in the National Center for Biotechnology Information Gene Expression Omnibus (accession number GSE52005). Analyses were performed using GeneSpring GX 7.3 software (Agilent Technologies) [21, 22]. Transcripts were first selected if present in >10% of all samples and were then filtered to select the most variable probes. We used several analytical tools. First, we used GeneSpring for supervised analysis with all samples (140 samples), using statistical filtering and class comparisons to identify transcripts differentially expressed between study groups. The nonparametric MannCWhitney test for comparisons across groups was used, with a < .05. Nilvadipine (ARC029) Second, we performed functional analyses of differentially expressed genes using modular analysis [23]. Gene expression levels were compared between each time point after vaccination and baseline (before vaccination) on a module-by-module basis. Modular transcript content and annotations are available at: http://www.biir.net/public_wikis/module_annotation/V2_Trial_8_Modules. Third, to confirm the findings from your modular analyses, gene expression values were log2 transformed and analyzed using a linear mixed model for the LAIV and TIV cohorts separately. Specifically, time was included in the model as a categorical variable, with a spatial power covariance matrix to account for correlation because subjects experienced repeated measurements. Each time point was then compared to INPP5K antibody baseline. JMP Genomics 6.0 software (SAS Institute, Cary, NC) was used for this analysis. Genes with a value of <.01 were considered differentially expressed [24]. Statistical analysis of demographic data was performed using Graph Pad Prism. MannCWhitney assessments were used for continuous variables, and 2 and Fisher exact tests were utilized for categorical variables. Antibody titer correlations were performed using the Spearman nonparametric test on Sigma Plot. Circulation cytometry data were Nilvadipine (ARC029) analyzed using the linear mixed model approach explained for microarray data. The data were log2 transformed, and a Bonferroni correction was used to adjust for multiple screening. RESULTS Immunization With LAIV and TIV Induce Distinct Changes in B Cell Populations We immunized 20 children who received LAIV and 17 children who received TIV (Table ?(Table1).1). Sequential circulation cytometry samples from all 4 time points were available for 16 in the LAIV group and 13 in the TIV group. Fourteen of 37 children (7 from each group) experienced adverse events after vaccination, all of which were upper respiratory tract symptoms. In the LAIV group, we found a significant increase at 30 days after vaccination in the complete numbers of naive, memory, and transitional B cells, compared with baseline (< .05), but there were no significant differences in the numbers of plasmablasts and plasma cells. Children immunized with TIV showed a significant increase in complete numbers of plasmablasts at day 7 after vaccination (< .01) but no significant changes in the numbers of naive, memory, and transitional B cells (Physique ?(Physique11< .05 and **< .01; NS, no statistical significance). Bars represent median.